Cancer Biomarker Global Market Report 2023

“Cancer Biomarker Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer biomarker market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer biomarker? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The cancer biomarker market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Biomarkers Type: Protein Biomarkers; Genetic Biomarkers; Other Cancer Biomarkers

• 2) By Profiling Technologies: Omics Technologies; Imaging Technologies; Immunoassay; Bioinformatics; Cytogenetics

• 3) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Thyroid Cancer; Kidney Cancer; Other Cancers

• 4) By Application: Diagnostics; Research And Development; Prognostics; Risk Assessment; Other Applications

• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific, Inc.; QIAGEN N.V.; Illumina, Inc.; Bio-Rad Laboratories, Inc.

• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

• Time series: Five years historic and ten years forecast.

• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the cancer biomarker market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMerieux SA, Becton, Dickinson and Company and Merck Millipore.

The global cancer biomaker market is expected to grow from $17.08 billion in 2022 to $19.80 billion in 2023 at a compound annual growth rate (CAGR) of 15.92%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cancer biomaker market is expected to reach $33.69 billion in 2027 at a CAGR of 14.21%.

The cancer biomarker market consists of sales of epigenetic biomarkers, and metabolic biomarkers for various cancers such as melanoma, leukemia, bladder cancer, non-hodgkin's lymphoma, endometrial cancer, pancreatic cancer, and liver cancer. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

A cancer biomarker refers to a biological molecule present in the blood, tissues, or other bodily fluids, that indicates the presence of normal or abnormal activity, as well as a condition or disease. Cancer biomarkers are used to characterize alterations in the tumor.

North America was the largest region in the cancer biomaker market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of cancer biomarker are protein biomarkers, genetic biomarkers, and other that uses omics technologies, imaging technologies, immunoassay, bioinformatics, and cytogenetics profiling technologies. Protein biomarkers refer to detectable flags in a patient's blood that corresponds with significant events or signal distinct states in a biological process, such as disease progression. Protein biomarkers are used to perform accurate disease diagnosis. The cancer biomarker is used in various cancer such as breast cancer, lung cancer, colorectal cancer, prostate cancer, thyroid cancer, kidney cancer, and other cancers. It is used in diagnostics, research and development, prognostics, risk assessment, and other applications.

The rising incidence of cancer is driving the growth of the cancer biomarker market. The cancer incidence rate is the number of new cancers of a specific site/type that occur in a given population during a given year, represented as cancers per 100,000 people at risk. The increasing incidence of cancer is leading to the widespread use of cancer biomarkers because it helps in assessing disease risk, screening for occult primary tumors, identifying benign from malignant signs, or separating one form of malignancy from another. For instance, according to the 2021 American Cancer Society report, 1.8 million new cases of cancer were diagnosed in 2020. Furthermore, the National Cancer Institute, a US-based government organization that is a part of the National Institutes of Health, reported in September 2020 that 1,806,590 new cancer cases were registered, which indicated a 43% increase from the previous year. Therefore, the rising incidence of cancer packaging is expected to propel the growth of the cancer biomarker market in the coming years.

Technological advancement is a key trend gaining popularity in the cancer biomarker market. Major market players are developing advanced technologies such as artificial intelligence (AI), deep learning (DL), and machine learning (ML) to sustain their position in the cancer biomarker market. These techniques are being used to tackle the problems associated with finding cancer biomarkers, where processing enormous volumes of molecular and imaging data are beyond the capabilities of conventional statistical studies and tools. For instance, in December 2021, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceuticals and diagnostics company introduced uPath Ki-67 (30-9), uPath ER (SP1), and uPath PR (1E2), three new automated digital pathology algorithms that will be used as a biomarker for image analysis for breast cancer. This image analysis for breast cancer uses pathologist-trained deep learning algorithms to speed up the estimation of Ki-67, ER, and PR tumor cell nuclei positive.

In May 2021, GE Healthcare, a US-based company engaged in diagnostics, therapeutics, and monitoring through intelligent devices, decision support tools, data analytics, and applications acquired Zionexa for an undisclosed amount. Through this acquisition, GE Healthcare expanded its pipeline of neurology and oncology tracers to aid doctors in treating patients individually. Zionexa is a France-based company that develops in-vivo biomarkers for directing tailored treatments in oncology.

The countries covered in the cancer biomarker market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The cancer biomarkers market research report is one of a series of new reports from The Business Research Company that provides cancer biomarkers market statistics, including cancer biomarkers industry global market size, regional shares, competitors with a cancer biomarkers market share, detailed cancer biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the cancer biomarkers industry. This cancer biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.